Rate Of Return$SINOMAB BIO-B(03681.HK)China Antibody (03681) is currently at a critical stage of survival, with extremely bleak prospects and a low probability of survival. Unless the aforementioned key positive reversals occur, the risk of the company's value going to zero is far greater than the possibility of a 'phoenix rising from the ashes.' Investors must treat it with a 'lottery mentality' and be highly vigilant about its 'delisting risk.'
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
